APIM THERAPEUTICS IS A BIOTECHNOLOGY COMPANY DEDICATED TO THE DEVELOPMENT OF NOVEL ANTI-CANCER AGENTS TARGETING DNA REPAIR AND CELL CYCLE CONTROL

At APIM THERAPEUTICS AS we focus on the development and commercialization of novel anti-cancer therapies potentiating chemotherapy induced responses in cancer cells. Our approach is based on targeting PCNA, a “hub” protein regulating cell responses to stress e.g.  e.g. in response to several anti-cancer agents. Through development of innovative peptide drugs which contain a novel PCNA-interacting Peptide Motif termed APIM, the company offers a novel intervention point allowing cancer-specific tumor cell elimination. The company's lead drug, ATX-101, is set to enter the clinic in early 2016.

 

DRUG PIPELINE

Drug PipelineAPIM Therapeutics AS is developing a pipeline of peptide drugs that target PCNA-dependent stress responses in cancer cells. Our lead compound, ATX-101, has shown proof-of-concept in multiple preclinical in vitro and in vivo cancer models.

Learn More

 

ABOUT US

APIM Therapeutics AS is a venture capital supported spin off from the Norwegian University of Science and Technology (NTNU) at Trondheim, Norway.

Learn More

 

APIM THERAPEUTICS SNAPSHOT

APIM Therapeutics SnapshotDownload this pdf for a short company summary.

A publication in Translational Oncology describing ATX-101 validation in bladder cancer is available here. A recent 2-page article on the relevance of APIM's  targeted mechanism of action and bladder cancer is available here.